Published: 22 July 2019
Author(s): William Gansheng Shi, Mark Crowther
Issue: July 2019
Section: Editorial

The direct oral anticoagulants (DOACs) (apixaban, rivaroxaban, betrixaban, edoxaban and dabigatran) have gradually replaced vitamin K antagonists (VKAs) as the mainstay anticoagulation therapy. However, lack of specific reversal agents has been consistently raised as a concern since the introduction of the DOACs. Major bleeding and invasive procedures are common clinical settings where DOAC reversal may be required; further a high frequency of co-morbid conditions makes it likely that patients treated with DOACs will require such interruptions of their therapy.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness